Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Editor In Chief, Pharma, APAC
Japan
+32 year(s) experience
Scrip
Take a brief audio tour around the main biopharma industry events of the past week, as brought to you by Scrip's global team, in this podcast version of Five Must-Know Things.
Topic Coronavirus M A
Scrip
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Topic Sales Earnings
Scrip
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team
Scrip
Join us for an audio roundup of major events in the international biopharma industry over the past week, as covered by Scrip's global team
Scrip
Join us for an audio roundup of major events in the international biopharma industry over the past week, as reported by Scrip's global team
Topic Coronavirus Clinical Trials
Scrip
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Scrip
Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Scrip
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Topic Cell & Gene Therapy
Scrip
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical sector.
Topic Coronavirus M A
Scrip
Spreading China outbreak not a point of focus for companies or analysts in quarterly results briefings.
Topic Coronavirus
Scrip
Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.
Scrip
Daiichi Sankyo unveils further restructuring moves, this time mainly in its R&D functions in Japan, as part of an ongoing strategic pivot towards oncology.
Topic Research
Scrip
Chugai's new CEO Tatsuro Kosaka took up his position in March and is charged with taking the major Japanese company through the next stage of development as key products reach the global market and others begin to face biosimilar competition. In this first part of a two-part exclusive interview, he outlines the firm's vision, approach to R&D and how the strategic alliance with Roche is playing out.
Scrip
As part of broader efforts to pursue novel approaches to common neurological disorders, Eisai uses iPSC-derived cells to help identify potential new drug therapies for Parkinson's.
Topic Parkinsons disease
Scrip
Following a priority review, Japan has approved AstraZeneca’s Tagrisso for the first-line treatment of inoperable or recurrent EGFR mutation-positive NSCLC, further strengthening the drug’s position in this setting.
Topic Cancer
Scrip
23 Nov 2020
Pink Sheet
26 Oct 2020
Scrip
21 Oct 2020
Scrip
20 Oct 2020
Scrip
15 Oct 2020
Scrip
15 Oct 2020
Scrip
13 Oct 2020
Scrip
09 Oct 2020
Scrip
07 Oct 2020
Pink Sheet
29 Sep 2020
Scrip
17 Sep 2020
Pink Sheet
16 Sep 2020
Pink Sheet
04 Sep 2020
Medtech Insight
26 Aug 2020
Scrip
26 Aug 2020
